Generated by AI
Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for inflammatory and immune-mediated diseases. The company’s lead program centers on SL-325, a DR3 antagonist antibody designed to target the TL1A/DR3 pathway, which is being studied for inflammatory bowel disease and related conditions. Shattuck Labs is also advancing SL-425, a half-life extended version of SL-325, along with additional preclinical DR3-based antibody candidates. Its research is built around protein engineering and novel therapeutic designs intended to modulate immune signaling more precisely. Based in Austin, Texas, Shattuck Labs operates within the broader biopharmaceutical market, where its current pipeline is aimed at addressing immune-driven diseases with significant unmet medical need.
Website500 West 5th Street
Austin, TX, 78701
United States
The latest articles about STTK.
Detailed price information for Shattuck Labs Inc (STTK-Q) from The Globe and Mail including charting and trades.
Detailed price information for Shattuck Labs Inc (STTK-Q) from The Globe and Mail including charting and trades.
Summary of Jun 8's posts. Generated by AI.
Summary of Jun 5's posts. Generated by AI.
Summary of Jun 8's posts. Generated by AI.
Investors talking about STTK also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.